BR112013015798A2 - composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, e, composição farmacêutica - Google Patents

composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, e, composição farmacêutica

Info

Publication number
BR112013015798A2
BR112013015798A2 BR112013015798A BR112013015798A BR112013015798A2 BR 112013015798 A2 BR112013015798 A2 BR 112013015798A2 BR 112013015798 A BR112013015798 A BR 112013015798A BR 112013015798 A BR112013015798 A BR 112013015798A BR 112013015798 A2 BR112013015798 A2 BR 112013015798A2
Authority
BR
Brazil
Prior art keywords
imaging agent
agent composition
composition
preparing
pharmaceutical composition
Prior art date
Application number
BR112013015798A
Other languages
English (en)
Inventor
Wilson Anthony
Indrevoll Bard
Hiscock Duncan
Eberhard Glaser Matthias
Iveson Peter
Bhalla Rajiv
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/975,425 external-priority patent/US20120165650A1/en
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of BR112013015798A2 publication Critical patent/BR112013015798A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013015798A 2010-12-22 2011-12-19 composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, e, composição farmacêutica BR112013015798A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/975,425 US20120165650A1 (en) 2010-12-22 2010-12-22 Her2 binders
US201161438297P 2011-02-01 2011-02-01
US201161510520P 2011-07-22 2011-07-22
US201161541314P 2011-09-30 2011-09-30
PCT/US2011/065803 WO2012087912A1 (en) 2010-12-22 2011-12-19 Her2 binding peptides labelled with a 18f - containing organosilicon compound

Publications (1)

Publication Number Publication Date
BR112013015798A2 true BR112013015798A2 (pt) 2019-09-24

Family

ID=45464124

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013015798A BR112013015798A2 (pt) 2010-12-22 2011-12-19 composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, e, composição farmacêutica

Country Status (13)

Country Link
US (1) US20130295010A1 (pt)
EP (1) EP2661284A1 (pt)
JP (1) JP2014503547A (pt)
KR (1) KR20130132939A (pt)
CN (1) CN103402550B (pt)
AU (1) AU2011349486A1 (pt)
BR (1) BR112013015798A2 (pt)
CA (1) CA2822698A1 (pt)
MX (1) MX2013007363A (pt)
NZ (1) NZ612327A (pt)
RU (1) RU2013128360A (pt)
SG (1) SG191338A1 (pt)
WO (1) WO2012087912A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
CA2822815A1 (en) * 2010-12-22 2012-06-28 Ge Healthcare Limited Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota
GB201209082D0 (en) * 2012-05-24 2012-07-04 Ge Healthcare Ltd Purification method
KR20160055728A (ko) * 2013-06-27 2016-05-18 지이 헬쓰케어 리미티드 Her2 결합제의 용도
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322451D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Purification method and compositions
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
MX2021008999A (es) * 2019-01-30 2021-11-04 Univ Muenchen Tech Agentes radiotrazadores y agentes terapeuticos de modo doble, que se unen al antigeno de membrana especifico de la prostata.
CN110251695B (zh) * 2019-07-10 2021-12-21 莎穆(上海)生物科技有限公司 一种靶向her2的放射性配合物及其制备方法和应用
CN114317385B (zh) * 2021-11-11 2024-02-13 元本(珠海横琴)生物科技有限公司 一种促进her2亲和体蛋白分泌表达的发酵培养基及发酵工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
ES2319426T3 (es) * 2003-07-04 2009-05-07 Affibody Ab Polipeptidos que presentan afinidad de union por her-2.
GB0428012D0 (en) 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
WO2008049866A1 (en) * 2006-10-27 2008-05-02 Affibody Ab New chelating compound
US8303960B2 (en) * 2007-02-27 2012-11-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Radiolabeled affibody molecules
EP2072525A1 (en) * 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2

Also Published As

Publication number Publication date
EP2661284A1 (en) 2013-11-13
JP2014503547A (ja) 2014-02-13
CN103402550B (zh) 2015-12-09
SG191338A1 (en) 2013-07-31
KR20130132939A (ko) 2013-12-05
WO2012087912A1 (en) 2012-06-28
MX2013007363A (es) 2013-09-26
US20130295010A1 (en) 2013-11-07
NZ612327A (en) 2015-03-27
AU2011349486A1 (en) 2013-07-25
CN103402550A (zh) 2013-11-20
RU2013128360A (ru) 2015-01-27
CA2822698A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
BR112013015796A2 (pt) composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, método de preparar um quelante 18f-nota, e, composição farmacêutica.
BR112013015798A2 (pt) composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, e, composição farmacêutica
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
BR112013033811A2 (pt) composição, método de preparação da composição, e, composto
BR112013013311A2 (pt) agente terapêutico de indução de citotoxicidade
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
EP2535339A4 (en) POLYMORPHES OF DASATINIB, METHOD OF MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS THEREOF
HK1202415A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15- hetre and methods of use thereof dgla15-ohepa/ 15-hetre
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
BR112012023355A2 (pt) composto, composição farmacêutica e método de ruptura da interação nek2/hec1
BR112013014189A8 (pt) composição farmacêutica, uso de um agente de potencialização e uso de uma composição
BRPI0921507A2 (pt) composição, método de preparação de um excipiente, comprimido farmacêutico e método de preparação do mesmo
BR112013015085A2 (pt) composição farmacêutica, método para preparar uma composição, e, uso de composição
HRP20180793T1 (hr) Farmaceutski pripravak i oblik doziranja koji sadrži dronedaron, te postupak njegove priprave
BR112014003556A2 (pt) método de tratamento de vírus, e, composição farmacêutica
BR112013010709A2 (pt) derivado de ácido trans-2-decenoico e agente farmacêutico contendo o mesmo
HK1188791A1 (zh) 新型八氫噻吩並喹啉衍生物、包含所述衍生物的藥物組合物及它們的用途
BR112013014435A2 (pt) membro de hppe e método de preparação de um membro de hppe
BRPI1013525A2 (pt) agente farmacêutico, composição farmacêutica, e, método de tratamento de influenza
DK2588097T3 (da) Farmaceutiske sammensætninger omfattende paracetamol og fremgangsmåde til fremstilling af samme
EP2621542A4 (en) COMPOSITIONS USEFUL FOR DETECTION, IMAGING AND TARGET PROCESSING, AND METHODS OF MAKING AND USING THE SAME
IL236562A0 (en) A pharmaceutical preparation with an improved flow capacity, a medical agent, and a method for its production and use
BR112013009647A2 (pt) derivado de vitamina, composição farmacêutica, agente terapêutico, e, composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.